公开(公告)号：EP4353723A1

公开(公告)日：2024-04-17

申请号：EP22819443.7

申请日：2022-06-02

申请人： GENZYME CORPORATION

发明人： CHEN, Minhua ,  SHI, Jiaming ,  ZHANG, Jing

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/4545 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  A61P25/00 ,  A61P37/06

CPC分类号： A61K31/437 ,  A61K31/4545 ,  A61P25/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  A61P37/06 ,  C07D471/04

摘要： The present invention relates to a new crystal form of tolebrutinib (hereinafter referred to as "compound I"), a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of same in the preparation of a BTK inhibitor drug and a drug for treating multiple sclerosis. The crystal form of tolebrutinib provided has one or more improved properties compared with the prior art, and is of great value to the optimization and development of drugs in the future.